• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

PET aids neuroblastoma management decisions

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 31 No 9
Volume 31
Issue 9

Children's hospitals in Cincinnati and Memphis, TN, have established the value of FDG-PET for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.

Children's hospitals in Cincinnati and Memphis, TN, have established the value of FDG-PET for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.

Lead author Dr. Susan E. Sharp, an assistant professor of clinical radiology at Cincinnati Children's Hospital Medical Center, and colleagues reviewed a total of 113 paired planar and SPECT Iodine-123I-metaiodobenzylguanidine (MIBG) and FDG-PET/CT scans in 60 patients with neuroblastoma. The investigators found that for stage 1 and stage 2 neuroblastoma patients, FDG-PET depicted more primary or residual neuroblastoma. However, they also found MIBG imaging may be needed to exclude higher stage disease that has spread to the bone or bone marrow (J Nucl Med 2009;50[8]:1237-1243).

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.